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Objectives: This article has two main objectives. One is to examine the
correspondence between World Bank pharmaceutical policies in Latin America
and recommendations made in World Bank documents, and the other is to
analyze the implementation of these recommendations.
Methodology: Bibliographical and document review, and in-depth interviews.
Results: The authors claim that health care systems spend a relatively high
percentage of their resources on purchasing drugs, while the poor spend a
disproportionate segment of their income on drugs. There is ample evidence in
the literature that these medicines are poorly utilized. The explicit goals of the
reforms led by the World Bank were to improve equity, efficiency, quality, and
user satisfaction --difficult goals to achieve if medications are not affordable.
The authors found that the World Bank identified and recommended a set of
suitable measures to be taken to meet Latin America's pharmaceutical needs.
They note that these recommendations were, however, ignored in the reforms
supported by the World Bank and that the majority of loans that included
pharmaceutical measures allocated funds only for drug purchases. The authors
propose four hypotheses for understanding the World Bank’s failure to support its
recommendations: 1) a lack of pharmaceutical experts with influence in the World
Bank; 2) the World Bank's tendency to exclude interventions not related to
infrastructure, institutional development, or equipment purchases; 3) opposition
by countries to financing pharmaceutical interventions; 4) the liberal ideology of
World Bank policy decision-makers. The authors analyze these hypotheses, but
conclude that it is difficult for external researchers to verify their validity, given the
Bank’s lack of transparency.
Conclusions: The pharmaceutical needs of Latin America’s health systems
correspond closely to those expressed in the 1993 World Bank Report which
dealt with the need to rationalize drug expenditures and use. This would include
improving production, prescribing, dispensing, consumption, and industry
regulation --areas that require technical help. The WHO contributes to some
extent, but its resources are limited. World Bank loans could be used to
complement WHO efforts.

